Lee Sooyeon, Park Jong-Min, Park Sang-Ho, Kim Eun-Hee, Hahm Ki Baik
CHA Cancer Prevention Research Center, CHA Cancer Institute, CHA University, Seoul ; College of Pharmacy, CHA University, Pocheon.
CHA Cancer Prevention Research Center, CHA Cancer Institute, CHA University, Seoul.
J Cancer Prev. 2013 Jun;18(2):107-12. doi: 10.15430/jcp.2013.18.2.107.
The guideline of the Korean College of Helicobacter and Upper Gastrointestinal Research group for Helicobacter pylori infection was first produced in 1998. Definite indication for H. pylori eradication is early gastric cancer in addition to the previous indications of peptic ulcer (PUD) including scar lesion and marginal zone B cell lymphoma (MALT type). Though treatment regimen was similar, Japan government declared the inclusion of H. pylori eradication in patients with H. pylori-associated chronic gastritis, suggesting the treatment guideline is quite different between Korea and Japan from February 21, 2013. The prime rationale of Japanese extended treatment guideline for H. pylori infection was based on the drastic intention to prevent gastric cancer according to their beliefs that H. pylori eradication can decrease gastric cancer incidence as well as mortality. In this review, the discrepancy in treatment guideline between Korea and Japan will be explained.
韩国幽门螺杆菌与上消化道研究组关于幽门螺杆菌感染的指南于1998年首次制定。除了消化性溃疡(PUD)(包括瘢痕病变)和边缘区B细胞淋巴瘤(MALT型)等先前的指征外,幽门螺杆菌根除的明确指征是早期胃癌。尽管治疗方案相似,但自2013年2月21日起,日本政府宣布将幽门螺杆菌相关慢性胃炎患者纳入幽门螺杆菌根除治疗范围,这表明韩国和日本的治疗指南存在很大差异。日本扩大幽门螺杆菌感染治疗指南的主要依据是,他们坚信根除幽门螺杆菌可以降低胃癌发病率和死亡率,从而有强烈意愿预防胃癌。在本综述中,将解释韩国和日本治疗指南的差异。